Question Bank › The bottleneck is inside and being paid away

The bottleneck is inside and being paid away

The bottleneck is inside and being paid away: internal limits on serving live demand, with removal already funded

Calls Tested
500
Answered YES
15
Hit Rate
3%
rare by design

Intra-Cellular Therapies, Inc. (ITCI) — this company's answers

NO on the Q4 2017 call 2018-03-01 D
The model's full reasoning — Q4 2017 call → NOThe question asks whether management conveys that the main thing standing between the company and meaningful business is the company's own capability (capacity, people, facilities, throughput) rather than a shortage of demand, AND that the company is already spending real money and effort to remove that internal limit. Looking at the transcript, this is a biotech company (Intra-Cellular Therapies) in clinical development for drugs like lumateperone. The discussion is about clinical trials, NDAs, regulatory filings, etc. There is no discussion of "live demand pressing in" — no waiting customers, orders, or business activity. The company is still in clinical development stage, not yet commercialized. They mention "pre-commercial activities" and preparing for launch, but there's no demand exceeding capacity situation described. The competitors are clinical trial results, regulatory filings, not production capacity. The context is a drug development company in late-stage clinical trials. There's no indication of demand pressing against capacity. Management talks about preparing NDAs, conducting trials, etc. There's no language about being unable to serve demand, allocating output, or queued work. Therefore, the answer is clearly NO.

← Back to the full ITCI analysis

Show the exact prompt the model was given
Using ONLY the supplied earnings call transcript and no outside information: On this call, does management convey that THE MAIN THING STANDING BETWEEN THE COMPANY AND MEANINGFULLY MORE BUSINESS RIGHT NOW IS THE COMPANY'S OWN CAPABILITY — its capacity, people, facilities, throughput, or ability to deliver — rather than a shortage of demand, AND that the company is ALREADY SPENDING REAL MONEY AND EFFORT to remove that internal limit, with the business waiting on the other side already visible today? Answer YES when management's own words convey, in whatever form fits the industry, ONE coherent present-tense situation with all three present: (1) LIVE DEMAND PRESSING IN: real business — orders, customers, committed work, volumes, or activity already arriving or already in hand — exceeds or presses against what the company can currently produce, deliver, staff, install, or serve, grounded in actual current behavior (waiting buyers, stretched lead times, allocated output, work queued) rather than in pipeline or market opportunity; (2) THE LIMIT IS THE COMPANY'S OWN: management identifies its own capability, not customer hesitation, competition, macro softness, or purchased-input shortages alone, as the binding constraint; and (3) REMOVAL ALREADY UNDERWAY: concrete expansion — building, hiring, commissioning, qualifying, adding shifts or sites, bringing in outside capability — is executing now or committed and in motion, not merely planned, with management treating the race to serve the waiting business as its central task and the fuller contribution still ahead of the reported results. Answer NO if the company can comfortably serve everything asked of it. NO if the constraint is chiefly inputs it buys with no unserved customers of its own behind it. NO if the tightness is a brief hiccup, ordinary seasonality, or already resolved. NO if the expansion is contemplated, budgeted for later, or contingent on financing or approvals not in hand. NO if management is mainly cutting, consolidating, or defending weakness. NO if the situation appears only in an analyst's question that management does not itself affirm. Use only the supplied transcript. Answer only YES or NO.

Companies that answered YES

TickerCompanyCallDateCall grade
BRBR BellRing Brands, Inc. Q4 2023 2023-11-21 B+
PRPH ProPhase Labs, Inc. Q1 2023 2023-05-11 F
TSSI TSS, Inc. Q4 2022 2023-04-03 D
TACT TransAct Technologies Incorporated Q4 2022 2023-03-08 A
PI Impinj, Inc. Q4 2022 2023-02-08 B+
CRL Charles River Laboratories International Q2 2022 2022-08-03 C
SYM Symbotic Inc. Q3 2022 2022-08-01 B+
OGI OrganiGram Holdings Inc. Q3 2022 2022-07-14 B+
GFS GLOBALFOUNDRIES Inc. Q3 2021 2021-11-30 A
HNRG Hallador Energy Company Q3 2021 2021-11-09 C+
FSS Federal Signal Corporation Q1 2018 2018-05-12 A
AOSL Alpha and Omega Semiconductor Limited Q2 2018 2018-02-07 B
ZBH Zimmer Biomet Holdings, Inc. Q2 2017 2017-07-30 F
PLAB Photronics, Inc. Q2 2017 2017-05-17 C+
GOGO Gogo Inc. Q1 2016 2016-05-06 C+

How the model reasoned

ZBH · Q2 2017 → YESThe question is about whether management conveys that the main thing standing between the company and more business is their own capability, and they're already spending to remove that limit, with dem...YES The transcript shows live demand pressing in through back orders, surgeons waiting to move business back until supply is restored, and steady market demand with recapture opportunities already in hand.
SYM · Q3 2022 → YESThe question is: Does management convey that THE MAIN THING STANDING BETWEEN THE COMPANY AND MEANINGFULLY MORE BUSINESS RIGHT NOW IS THE COMPANY'S OWN CAPABILITY — its capacity, people, facilities, th...
BRBR · Q4 2023 → YESThe question is about whether management conveys that the main thing standing between the company and more business is their own capability, and they're already spending to remove that limit, with dem...

More from the question bank

Repeat pull from proven relationships plus rExternal validators convergingSmall company, disproportionate current winsProfit machinery upgraded while volume stillTone of discovery: management sounds newly sSkeptical premise dismantled with receiptsAll questions →
Not investment advice. Artul.ai publishes AI-generated earnings-call quality grades and expected-volatility estimates — never buy or sell recommendations. We tested over 1,600 predictive hypotheses against 165,000 transcripts; the honest result, including what failed, is documented in our methodology.